CITIC Capital Bids $3.6 Billion to Acquire China Biologic Products

CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products, one of China 's top five plasma-based biopharmas. The bid, which came at a 34% premium to the previous close, was unsolicited and non-binding. Headquartered in Beijing , CBPO operates plasma-gathering facilities and offers 20 plasma-based products. The offer, priced at $110 per share, represents a P/E ratio of 37 based on the past 12 months, but only 16.5 on the anticipated 12 months. More details.... Stock Symbol: (NSDQ: CBPO) Share this with colleagues: // //